Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions
Safety results show Ampligen is generally well tolerated in the treatment of Post-COVID Conditions
Posted In: AIM